East Coast, USA-based firm Athenex (Nasdaq:ATNX), has announced several key strategic deals focused on China, aimed at furthering its oncology developments.
First, the firm says it has agreed a new joint venture (JV) with a subsidiary of Guangzhou Xiangxue Pharmaceutical to develop and commercialize T-cell receptor-engineered T cells (TCR-T), a cancer immunotherapy technology, based on a novel approach.
At the same time, Athenex has made a strategic expansion into biologics for oncology, gaining worldwide rights to a pegylated genetically modified human arginase from a subsidiary of Hong Kong-based Avalon Biomedical Management.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze